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Abstract: Immunosuppression based on calcineurin inhibitors (CNIs) has greatly improved organ transplantation, 
although subsequent nephrotoxicity significantly hinders treatment success. There are no currently available spe-
cific soluble biomarkers for CNI-induced nephrotoxicity and diagnosis relies on renal biopsy, which is costly, invasive 
and may cause complications. Accordingly, identification of non-invasive biomarkers distinguishing CNI-induced 
kidney tubular damage from that of other etiologies would greatly improve diagnosis and enable more precise 
dosage adjustment. For this purpose, HK-2 cells, widely used to model human proximal tubule, were treated with 
CNIs cyclosporine-A and FK506, or staurosporine as a calcineurin-independent toxic compound, and secretomes 
of each treatment were analyzed by proteomic means. Among the differentially secreted proteins identified, only 
fascin-1 was specifically released by both CNIs but not by staurosporine. To validate fascin-1 as a biomarker of CNI-
induced tubular toxicity, fascin-1 levels were analyzed in serum and urine from kidney-transplanted patients under 
CNIs treatment presenting or not isometric vacuolization (IV), which nowadays represents the main histological 
hallmark of CNI-induced tubular damage. Patients with chronic kidney disease (CKD) and healthy volunteers were 
used as controls. Our results show that urinary fascin-1 was only significantly elevated in the subset of CNI-treated 
patients presenting IV. Moreover, fascin-1 anticipated the rise of sCr levels in serially collected urine samples from 
CNI-treated pulmonary-transplanted patients, where a decline in kidney function and serum creatinine (sCr) eleva-
tion was mainly attributed to CNIs treatment. In conclusion, our results point towards fascin-1 as a putative soluble 
biomarker of CNI-induced damage in the kidney tubular compartment.
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Introduction
The calcineurin inhibitors (CNIs), cyclosporine A 
(CsA) and FK506, have been widely used in the 
prevention of allograft rejection since its intro-
duction in the late 1970s and early 1980s, 
respectively. Even now, most of solid organ 
transplanted patients are under a CNI-based 
immunosuppressant pattern. Despite its bene-
fits, CNIs produce several toxic side effects, the 
most relevant of which is renal toxicity. CNI-
induced nephrotoxicity has been etiologically 
attributed to its vasoconstrictor action and 
direct cytotoxic effects on tubular epithelial 
cells. Up to 76% of kidney transplanted patients 
show signs of CNIs nephrotoxicity after one year 
of transplantation, and up to 97% after ten 
years [1]. Histological findings associated to 
CNIs nephrotoxicity include arteriolopathy, 
tubular isometric vacuolization and thrombotic 
microangiopathy (TMA) in acute nephrotoxicity 
and arteriolar hyalinosis with interstitial fibro-
sis, tubular atrophy (IFTA), glomerulosclerosis 
and tubular microcalcifications in chronic neph-
rotoxicity. Nonetheless, CNIs side effects might 
be overestimated since most of these features 
are not exclusive of this pathology, making dif-
ficult to distinguish CNIs nephrotoxicity from 
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other injuries produced by factors like hyper-
tension or ischemia-reperfusion [2].
Over the recent decades, many efforts have 
been done to identify biomarkers that could 
detect early loss of renal function. Parameters 
such as serum creatinine and proteinuria 
detect late kidney dysfunction and are highly 
unspecific. Proteins such as cystatin C [3], 
KIM-1 (kidney injury molecule-1) [4], FABP (fatty 
acid binding protein) [5, 6], NGAL (neutrophil 
gelatinase associated lipocalin) [7-9], among 
others [10-12], are being validated as novel bio-
markers of kidney damage. Although these bio-
markers could potentially anticipate an increase 
in creatinine levels and loss of kidney function, 
do not inform on whether the histological 
lesions are actually CNI-specific or not. At pres-
ent, allograft biopsy and more specifically iso-
metric vacuolization remains the best diagnos-
tic option to detect kidney damage associated 
to CNIs treatment.
Considering all the above, there is an unmet 
need to find non-invasive soluble biomarkers 
for early detection of CNI-induced renal toxicity. 
To identify differentially secreted proteins that 
could indicate tubule specific injury due to CNIs, 
we have analyzed the conditioned media of 
CNI-treated cultured proximal tubular cells by a 
proteomic approach. To confirm their suitability 
as biomarkers, candidate proteins have been 
further validated by ELISA assays in blood and 
urine samples from kidney and pulmonary 
transplanted patients treated with CNIs.
Material and methods
Cell culture and treatment
HK-2 cells (ATCC nº CRL-2190; Manassas, VA, 
USA) were cultured as previously described 
[13]. Cells were seeded at 0.15 × 106 cells/mL 
and after 48 h, confluent cells were treated for 
24 h with the indicated dose of CsA (Calbiochem, 
San Diego, CA, USA), FK506 (kindly provided by 
Astellas Pharma, Tokyo, Japan), staurosporine 
(Sigma Aldrich, Saint Louis, MO, USA) or vehicle 
alone in FBS-free medium.
Cytotoxicity assay
CsA, FK506 and staurosporine-induced cyto-
toxicity was measured by the LDH release 
assay using a commercial kit (Cytotoxicity 
Detection kitPLUS (LDH), Roche, Mannheim, 
Germany) following instructions of the manu-
facturer. Each compound and dose was tested 
per triplicate in three different experiments per-
formed on different days. Cytotoxicity (Percen- 
tage of LDH release) was calculated according 
to the following:
% LDHrelease = (LDHmedia/LDHmedia + LDHLysate) × 
100
The subtoxic dose for each condition was deter-
mined as the highest dose that did not induce 
cell death, in order to avoid the unspecific 
release of intracellular proteins.
2D electrophoresis
Cells seeded on 60.1 cm2 culture plates (TPP, 
Trasadingen, Switzerland) were treated with 
subtoxical dose of each compound for 24 h in 
FBS-free medium. Ten ml of cell-free condi-
tioned media were concentrated 200-fold to a 
final volume of 50 µl using 3 kDa cut-off Amicon 
centrifugal filters (Millipore, Tullagreen, Ireland). 
Sixty µg of each concentrated medium was 
mixed with rehydration solution (8 M urea, 2% 
CHAPS, 0.28% DTT, 0.5% IPG ampholine buffer 
pH 3-11 and 0.002% bromophenol blue) to a 
final volume of 125 µl and separated by iso-
electric focusing in a 7-cm polyacrylamide gel 
with immobilized 3-11 pH gradient (IPGphor 
system, Amersham Biosciences, Freiburg, 
Germany). Gel strips with the focused proteins 
were equilibrated for 15 min in reducing SDS 
buffer (50 mM Tris, 6 M urea, 30% glycerol, 2% 
SDS and 1% DTT), followed by 15 min incuba-
tion in alkylating SDS buffer (SDS buffer with 
4% iodoacetamide instead of DTT). The strips 
were placed on a 1 mm, 5 × 7 cm SDS-PAGE 
gel, and the second dimension was run in Tris-
Tricine-SDS Buffer [14] in a miniprotean III elec-
trophoresis system (Bio-Rad Laboratories, 
Hercules, CA, USA).
2-D differential analysis and mass spectrom-
etry
Gels were stained with colloidal Coomassie 
blue [15], digitized with a calibrated densitom-
eter (GS800; Bio-Rad Laboratories) and the 
resulting images analyzed using PDQuest 6.2 
software (Bio-Rad Laboratories). Software spot 
assignation was checked and validated indi-
vidually and spot intensity was normalized 
against the sum of intensity of the detected 
spots. The PDQuest software performed an 
automatic analysis using statistical criteria 
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(Student’s t-test) to detect differentially secret-
ed spots. Differential spots were excised, 
digested with trypsin and analyzed by MALDI-
TOF on an ultraflex TOF-TOF (Bruker Daltonics, 
Bremen, Germany). Calibrated spectra were 
processed using FlexAnalysis 2.2 software 
(Bruker Daltonics). Spots that were not identi-
fied by MALDI-TOF were addressed by LC-ESI-
MS/MS analysis on an esquire HCT IT mass 
spectrometer (Bruker Daltonics) coupled to a 
nano-HPLC (Ultimate; LC Packings, Amsterdam, 
The Netherlands). In this case, trypsin digested 
samples were loaded onto a 75-mm i.d., 15-cm 
PepMap nanoseparation column (LC Packings). 
MS/MS fragmentation (1.9 s, 100-2800 m/z) 
was performed on two of the most intense ions. 
The peak list was created with Data Analysis 
3.4 software (Bruker Daltonics). Proteins were 
identified using Mascot v.2.2.04 (Matrix 
Science, London, UK) to search the internation-
al protein index (IPI)-Human 3.26 database, 
with a mass tolerance < 100 ppm for MALDI-
TOF and 1.5 Da (precursor) and 0.5 Da (frag-
ment) for MS/MS, allowing two missed cleav-
ages for trypsin.
Immunoblotting
Five micrograms of cell extract and 35 µL of 
culture media were run on SDS-PAGE gels and 
transferred to polyvinylidene fluoride (PVDF) 
membranes. Blots were blocked with 5% 
skimmed milk in PBST and probed with anti-
fascin-1 antibody (HPA005723; Sigma-Aldrich) 
diluted 1:500 in blocking solution. Anti-MAPK 
antibody (06-182, Millipore) diluted 1:1000 in 
blocking solution was used as loading control.
Patients
Kidney transplanted patients, non-transplant-
ed chronic kidney disease (CKD) patients and 
healthy individuals were included in the study 
(Supplementary Tables 1, 2 and 3). Inclusion 
criteria for kidney transplanted patients were: 
less than one year after transplantation and 
CNI-based immunosuppression combined with 
MMF and/or prednisone. Biopsy was indicated 
in patients with allograft dysfunction, protein-
uria or as surveillance biopsy. None of these 
patients received intravenous immunoglobu-
lins, iodine contrast or osmotic diuretics during 
the last month before biopsy. Banff criteria [16] 
were followed for histopathology damage 
assessment. All samples were collected shortly 
before biopsy to correlate the putative biomark-
ers with histology. Kidney transplanted patients 
were then further classified according to pres-
ence or absence of isometric vacuolization (IV). 
The evaluation and grading of IV was done fol-
lowing the schema described in [17]. In this 
study we considered positive IV when more 
than 5% of cortical tubules were involved. 
Inclusion criteria for non-transplanted patients 
were CKD in stage III and IV and a glomerular 
filtration rate between 15 and 60 ml/min 
(MDRD). Previous cardiovascular episodes 
were considered an exclusion criterion. 
Samples from pulmonary transplanted patients 
were used to validate the specificity of putative 
biomarkers. The inclusion criteria for this group 
were immunosuppressive regimen based on 
CNIs and normal kidney function before trans-
plantation (Supplementary Table 4). Previous 
transplantation of any other organ was consid-
ered an exclusion criterion.
Sample collection and analysis
For urine samples, 30 mL of fresh urine were 
collected and centrifuged for 10 minutes at 
1200 g (4°C) and supernatant conserved at 
-80°C. On the day of analysis, samples were 
thawed and centrifuged again for 10 minutes at 
1200 g (4°C), and supernatants were concen-
trated to a final volume of 500 µl using 3 kDa 
cut-off Amicon centrifugal filters (Millipore). For 
blood samples, 5 ml of whole peripheral blood 
were collected and mixed with EDTA, and cen-
trifuged for 10 minutes at 1200 g at room tem-
perature. The resulting plasma fractions were 
aliquoted and stored at -80°C. Serum creati-
nine levels and proteinuria were analyzed by 
the Jaffe reaction [18] and the pyrogallol meth-
od, respectively. Blood levels of CNIs were eval-
uated by EMIT (Enzyme Multiplied Immunoa- 
ssay Technique). All procedures followed the 
European Directives of Clinical Investigation 
and were approved by the Ethics Committee of 
Clinical Investigation of the Vall d’Hebron 
Hospital, Barcelona, Spain (PR(AG) 12/2010).
ELISA assays
Plasma and urine levels of fascin-1 and KIM-1 
were determined with commercially available 
ELISA kits (fascin-1: E91757Hu, USCN Life 
Science Inc., Wuhan, PRC; KIM-1: DKM 100, 
R&D Systems, MN, USA) following the manufac-
turer instructions. Urinary levels of fascin-1 and 
KIM-1 were assessed diluting concentrated 
urine with MilliQ water 100 and 20 times, 
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respectively. ELISA assays were analyzed using 
a Triturus autoanalyzer (Grifols SA, Barcelona, 
Spain). Adjustment of the calibration curve was 
calculated by using a 4-parameter logistic 
regression (4PL). The results obtained in urine 
were normalized by the urinary creatinine 
levels.
Statistical analysis
Statistics was performed with GraphPad Prism 
6 (GraphPad Software, Inc, CA, USA) and 
Statgraphics Plus 4.1 (Manugistics Inc., 
Herdnon, VA, USA) software. The experiments 
performed in vitro were analyzed using 
Student’s t-test. All tests used for ELISA data 
analysis were non-parametric. For two data 
group comparison a Student’s t-test with Welch 
correction was performed. When comparing 
more than two groups, a Kruskal-Wallis test 
was done followed by Dunn’s multiple range 
comparison. Correlation analysis was per-
formed using Pearson’s test.
Results
Identification of proteins specifically secreted 
in response to subtoxic doses of CNIs
To identify early soluble biomarkers predicting 
kidney outcome under CNIs treatment, we 
aimed to identify proteins specifically secreted 
Figure 1. Cyclosporine A (CsA), FK-506 and staurosporine-induced cytotoxicity in HK-2 cells. Cultured HK-2 cells 
were treated for 24 h with increasing doses of CsA (A), FK-506 (B) and staurosporine (C) in FBS-free medium. Cy-
totoxicity was assessed by LDH assay. Each experiment was done three times with three replicates per condition. 
Results were analyzed by univariate ANOVA and differences between untreated cells and each experimental condi-
tion using Bonferroni contrasts (*, P < 0.05 and **, P < 0.01).
Figure 2. Fascin-1 levels are increased in the secretomes of HK-2 cells treated with CsA and FK-506 but not stauro-
sporine. Cultured HK-2 cells were treated for 24 h with 5 µM CsA, 30 µM FK-506 and 1 nM staurosporine in FBS-free 
medium. Media were concentrated and 50 µg of protein were used to perform proteomic bidimensional analysis. 
Differential secreted proteins were identified by mass spectrometry. An enlarged view of the SSP6411 protein spot, 
corresponding to fascin-1 in each treatment condition, is shown.
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by cultured tubule cells in response to CNIs. To 
distinguish regulated secretion from the unspe-
cific leakage due to cell lysis caused by CNIs 
toxicity, we first analyzed the toxicity threshold 
of each drug. HK-2 cells were treated with 
increasing doses of the immunosuppressants 
CsA and FK506, and with staurosporine as pos-
itive control of cell death induction, and cyto-
toxicity was measured after 24 h by LDH assay. 
The subtoxic dose, defined as the highest dose 
not inducing significant LDH release to medi-
um, was then determined for each compound. 
As shown in Figure 1, 5 µM CsA, 30 µM FK506 
and 1 nM staurosporine were set up as the sub-
toxic doses upon 24 h treatment. HK-2 cells 
were then seeded on 60.1 cm2 culture plates, 
treated as indicated, and 10 ml of each condi-
tioned media were collected for proteomic 
analysis as stated in methods. A representative 
proteomic map of the secreted protein set, 
from now on secretome, is shown in Figure 2. 
Secretomes from each treatment condition 
were analyzed and compared with that from 
untreated control cells. Significantly altered 
protein spots were then collected and identi-
fied by mass spectrometry. Although several 
proteins were identified (see Table 1), only fas-
cin-1, corresponding to spot 6411, was over 
represented (fold change > 1) in secretomes 
from both CsA and FK506-treated cells and 
was not altered (fold change ≤ 1) by staurospo-
rine. A zoom box depicting fascin-1 spot on 
each condition is shown in Figure 2. The pres-
Table 1. Mean intensity and fold change of the differentially represented spots identified in the secre-
tomes of CsA, FK-506 and staurosporine-treated HK-2 cells
Spot intensities Fold change





3203 Ubiquitin carboxyl-terminal 
hydrolase isozyme L1
922.6 ± 29.1 1592.8 ± 13.9* 710.7 ± 32.6 1447.0 ± 49.1 1.7 0.8 1.6
6409 Plasminogen activator 
inhibitor-1
15042.0 ± 53.8 33362.5 ± 17.3* 15350.9 ± 28.1 14483.0 ± 51.3 2.2 1.0 1.0
7304 Glyceraldehyde-3-phos-
phate dehydrogenase
833.2 ± 63.7 2473.7 ± 17.9* 1385.2 ± 31.8 1474.3 ± 30.3 3.0 1.7 1.8
7303 Fructose-bisphosphate 
aldolase A
301.4 ± 27.7 678.5 ± 24.6* 690.9 ± 22.5* 959.0 ± 58.1 2.3 2.3 3.2
6411 Fascin-1 494.9 ± 43.3 1324.1 ± 115.1* 1109.5 ± 24.5* 510.1 ± 89.6 2.7 2.2 1.0
2206 Galectin-1 1702.8 ± 9.3 3133.7 ± 16.5 1723.9 ± 37.3 3139.5 ± 19.4* 1.8 1.0 1.8
3410 Fructose-bisphosphate 
aldolase A
1067.7 ± 78.8 610.4 ± 112.7 862.7 ± 84.7 3510.2 ± 8.0* 0.6 0.8 3.3
7408 Pyruvate kinase isozymes 
M1/M2
964.0 ± 104.9 1909.2 ± 77.9 449.8 ± 61.6 2683 ± 15.4* 2.0 0.5 2.8
Spot intensities of each condition were compared with control spot intensities using Student’s t-test (*, P < 0.05).
Figure 3. Western blot validation of fascin-1 levels 
in the conditioned media of CsA and FK-506 treated 
cells. Cultured HK-2 cells were treated during 24 h 
with 2.5 and 5 µM CsA, 15 and 30 µM FK-506 and 
1 nM of staurosporine. Fascin-1 levels were detected 
by western blot using 35 µl of medium in each condi-
tion and 5 µg of whole cell extract (WCE). MAPKt was 
used as loading control of whole cell extracts. The 
experiment was performed three times with three 
replicates of each condition. Intensity of each band 
was assessed and data were analyzed by univariant 
ANOVA and Bonferroni’s contrast (*, P < 0.05). Fas-
cin-1 levels were significantly higher in CsA and FK-
506 conditioned media.
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ence of fascin-1 on the conditioned media of 
CsA and FK506 treated HK-2 cells was further 
validated by immunoblotting. As shown in 
Figure 3, levels of fascin-1 were correlating with 
the proteome data, since they were significant-
ly higher in the conditioned media from CsA 
and FK506-treated cells compared to those 
levels in media from control and staurosporine-
treated cells.
Analysis of fascin-1 levels in blood and urine 
from CNI-treated patients
Isometric vacuolization (IV) has been consid-
ered the main histological finding associated to 
CNI-induced toxicity upon the tubular compart-
ment [19, 20]. To investigate the usefulness of 
fascin-1 as a specific biomarker of CNI-induced 
tubular toxicity, we analyzed fascin-1 levels in 
serum and urine of kidney-transplanted 
patients under CNIs treatment presenting or 
not IV of tubule cells. As stated in the methods 
section, serum and urine samples from kidney 
transplanted patients were taken shortly before 
the kidney biopsy in order to accurately corre-
late fascin-1 levels with histological findings. 
Serum and urine from healthy volunteers were 
used as controls. To further corroborate that 
fascin-1 levels were specifically increased by 
CNIs treatment and not as a consequence of 
other kidney disease alterations, a third group 
of samples from non-transplanted CKD patients 
were included. Renal function markers includ-
Figure 4. Urinary levels of fascin-1 are higher in kidney transplanted patients showing isometric vacuolization of 
tubular cells. Urinary fascin-1 (A), serum creatinine (B), proteinuria (C) and urinary KIM-1 (D) levels were analyzed 
in healthy volunteers, non-transplanted chronic kidney disease (CKD) patients and kidney transplanted patients 
presenting or not isometric vacuolization (IV) of tubular cells. Fascin-1 and KIM-1 levels were assessed using ELISA 
assays and the results were normalized with urinary creatinine levels. Each sample was tested twice (variation coef-
ficient < 10%) and interplate controls were used. Data were analyzed using Kruskal-Wallis test and Dunn’s contrasts 
(*, P < 0.05). Fascin-1 levels in urine were significantly higher in kidney transplanted patients showing isometric 
vacuolization of tubular cells (A).
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ing creatinine and proteinuria, as well as the 
molecular marker of kidney injury KIM-1 were 
analyzed in those samples.
Our results indicate that urinary but not serum 
(results not shown) fascin-1 levels were statisti-
cally elevated in CNI-treated kidney-transplant-
ed patients exhibiting IV, in comparison to 
healthy, CKD patients or CNI-treated kidney-
transplanted patients without IV (Figure 4A). 
Moreover, both creatinine and proteinuria lev-
els were significantly elevated in kidney-trans-
planted patients with or without IV, and also in 
CKD patients, indicating that the increase in 
fascin-1 levels found in kidney-transplanted 
patients with IV is not a mere consequence of 
altered renal function but a specific feature of 
CNIs damage. Finally, KIM-1 levels were not 
statistically different between transplanted 
patients with or without IV, suggesting that kid-
ney injury per se is not the responsible of fas-
cin-1 upregulation.
Detection of fascin-1 in urine of lung trans-
planted patients
To investigate the potential role of urinary fas-
cin-1 as an early biomarker of CNI-induced kid-
ney damage, we analyzed fascin-1 levels in a 
time series of urinary samples from CNI-treated 
lung transplanted patients, where a decline in 
kidney function would be mainly attributed to 
CNIs treatment. Because kidney biopsy was 
not indicated in these patients, serum creati-
Figure 5. An increase in urinary fascin-1 levels precedes kidney dysfunction in lung transplanted patients. The 
graphs show the levels of fascin-1 in serial urine samples and the corresponding serum creatinine levels in lung 
transplanted patients 1 (A), 2 (B), 3 (C), 4 (D). Fascin-1 levels in urine were assessed using an ELISA assay and the 
results were normalized with urinary creatinine levels. Each sample was tested twice (variation coefficient < 10%) 
and interplate controls were used. Patients 2, 3 and 4 showed an increase of urinary fascin-1 levels preceding a loss 
of kidney function (B, C and D, respectively). Levels of creatinine serum above 1.5 mg/ml were considered altered 
kidney function. Tp: Transplantation.
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nine (sCr) levels were analyzed as suggestive of 
kidney endpoint toxicity of CNIs (see Table S4). 
Urinary fascin-1 levels were analyzed when 
urine samples were available. Our results show 
that lung transplanted patients with altered 
renal function (sCr > 1.5 mg/dl) exhibited a 
peak of urinary fascin-1 preceding the increase 
in sCr (Figure 5B-D). Moreover, patient 1, who 
presented normal renal function (sCr < 1.5 mg/
dl), showed undetectable levels of urinary fas-
cin-1 (Figure 5A). These results strengthen our 
previous data obtained in kidney transplanted 
patients and suggest that urinary fascin-1 lev-
els could predict loss of kidney function due to 
CNI-induced nephrotoxicity.
Discussion
Cell lines of kidney origin represent a simplified 
scenario to explore mechanistic insights into 
renal physiopathology, assess new therapeutic 
strategies or discover potential biomarkers of 
kidney injury in a system not influenced by the 
higher order regulatory elements of the whole 
kidney. In this sense, secretome profiling of cul-
tured cells has become a powerful strategy 
used to identify potential body fluid-accessible 
biomarkers. In the present work, we have used 
the human proximal tubule-derived cell line 
HK-2, which retain a phenotype indicative of 
well-differentiated PTCs [21], to identify poten-
tial protein biomarkers specifically released by 
proximal tubules in response to the cytotoxic 
action of CNIs in the tubule. By these means, 
we aim to discriminate the direct tubular toxici-
ty of CNIs from the overlapping hemodynamic 
effects occurring in the kidney. Accordingly, we 
assume that proteins secreted into the extra-
cellular media from cultured HK-2 cells exposed 
to CNIs are likely to resemble those secreted by 
human proximal tubular cells in the urine or 
blood of CNI-treated patients.
Both CsA and FK506 possess a very narrow 
therapeutic window and highly variable phar-
macokinetics [22]. CNIs levels in renal tissue 
are much higher than in blood due to local 
accumulation [23, 24] and the final dose at 
which epithelial cells of the proximal tubule are 
exposed is difficult to determine. Experimentally, 
too low concentrations will have none or little 
effect on cells, whereas too high concentra-
tions will trigger leakage of intracellular pro-
teins into the medium through the damaged 
plasmatic membrane upon cell death. Taking 
this into consideration, we set up the working 
dose of each drug as its highest subtoxic dose, 
as assayed by LDH release. As described [25-
27], our results show that FK506 cytotoxicity is 
much lower than that of CsA, since higher 
doses of FK506 are required to achieve signifi-
cant cell toxicity. To analyze the secretome pro-
file of HK-2 cells under these conditions, pro-
teomic maps of conditioned media from each 
treatment were compared and differentially 
secreted proteins were identified by mass spec-
trometry. It is noteworthy that the number of 
differentially secreted proteins identified in 
each condition is relatively low, likely related to 
the subtoxic drug doses used in this study. 
Among the proteins identified, we focused on 
those that were upregulated in both CsA and 
FK506 conditions since both drugs induce simi-
lar histological and functional injuries [28]. 
Moreover, candidate proteins whose levels 
were also affected by the apoptosis-inducer 
staurosporine were not considered by its poten-
tial involvement in non-specific cytotoxicity. 
Accordingly, only fascin-1 fulfilled these filtering 
criteria and was considered for further 
analysis.
In order to validate the suitability of fascin-1 as 
a biomarker of CNI-induced nephrotoxicity, fas-
cin-1 levels were analyzed in serum and urine 
of CNI-treated kidney-transplanted patients. 
Assessment of CNI-induced nephrotoxicity has 
been challenging since the original description 
of the pathology and basically relies on the his-
tological findings of renal biopsy. Systemic 
blood level monitoring of CNIs has proved to be 
of little help in predicting CNIs nephrotoxicity 
and specific and readily measurable soluble 
biomarkers are not currently available [29]. 
This mainly occurs because the interindividual 
susceptibility to CNIs nephrotoxicity is not 
directly related to the interindividual variability 
in systemic exposure to CNIs [19]. There are 
accumulating evidences that local renal con-
centrations of CNIs correlate with nephrotoxici-
ty, but it is also true that the local levels in the 
kidney allograft are not directly related to the 
systemic levels. Accordingly, we have observed 
that neither the presence of isometric vacuol-
ization nor fascin-1 levels correlated with sys-
temic blood levels of CNIs (Supplementary 
Figure 1A and 1B, respectively). Considering all 
the above, fascin-1 levels were correlated with 
isometric vacuolization (IV), which represents 
the most specific histological finding of renal 
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biopsy indicative of CNIs damage upon the 
tubular compartment [19, 20]. Our results show 
that a significant increase in fascin-1 levels was 
only observed in the subset of CNI-treated 
patients who evidenced CNI-induced toxicity. 
Moreover, CKD patients presented clinical 
signs of kidney dysfunction with unaltered lev-
els of fascin-1, indicating that fascin-1 is not 
merely released as a consequence of kidney 
injury, thus supporting the specificity of fascin-1 
as a biomarker of CNI-induced nephrotoxicity.
In addition to its specificity, potential biomark-
ers must be able to anticipate kidney dysfunc-
tion. The temporal relationship between fas-
cin-1 and the deterioration of renal function 
induced by CNIs was assessed in serially col-
lected urinary samples of CNI-treated lung 
transplanted patients. Although no kidney biop-
sy was available from these patients for histo-
logical diagnosis, it is not unreasonable to 
assume that loss of kidney function and the 
corresponding increase in serum creatinine 
(sCr) levels would be almost exclusively attrib-
utable to CNIs treatment. Our results show that 
in CNI-treated patients with sCr levels over 1.5 
mg/dl, a peak of fascin-1 levels was preceding 
the raising of sCr. Taken together, and despite 
the limited sample size of our patient cohorts, 
these results point towards urinary fascin-1 as 
a potential early biomarker of the direct and 
specific toxics effects of CNIs in kidney proxi-
mal tubule cells.
Fascins are actin-binding proteins that cross-
link filamentous actin into tightly packed paral-
lel bundles. These bundles are important for 
the organization and morphology of a wide 
range of sub-cellular structures that include 
dynamic and stable cell-surface protrusions 
that play diverse roles in cell-cell interaction 
and cell migration [30]. In this sense, fascins 
play a central role in the actin cytoskeleton re-
organization that accompanies epithelial-to-
mesenchymal transition (EMT) [31, 32], a pro-
cess shown to occur in proximal tubule epithe-
lial cells upon CNIs treatment [33]. This fact, 
together with our present results showing fas-
cin-1 translocation from cytosol to the extracel-
lular media, points towards a potential effect of 
CNIs modulating fascin-1 function and location. 
Since fascin-1 lacks an ER signal sequence tar-
geting to the secretory pathway, its presence in 
the extracellular media must be explained by 
non-classical secretion mechanisms such as 
secretory exosomes [34]. Accordingly, the pres-
ence of fascin-1 has been widely described in 
exosomes from many cancer cells [35-37]. As 
renal cells facing the urinary lumen, including 
tubular cells, actively release these vesicles, 
urinary extracellular vesicles have recently 
emerged as a potential source of soluble bio-
markers [38]. Thus, it is conceivable that fas-
cin-1 found in the extracellular media of CNI-
treated cells or the urine of CNI-treated patients 
could result from exosomes released by tubular 
cells.
In conclusion, our data suggest that fascin-1 
may represent a non-invasive urinary biomark-
er to assess tubular damage induced by CNIs. 
Early and specific detection of CNI-induced 
nephrotoxicity will allow in turn, adjustment of 
CNIs doses in order to achieve its optimal ther-
apeutic effect without developing nephrotoxici-
ty. To further assess the value of fascin-1 as a 
clinical biomarker, further clinical assays shall 
be validated in more extensive cohorts.
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Table S1. Individual clinical data of kidney transplanted patients’ group. Data of this group are split 
attending to absence or presence of isometric vacuolization. Presence of isometric vacuolization was 
considered when more than 5% of tubular sections were involved. The medical indication of the al-
lograft biopsy was acute allograft dysfunction, delayed graft function, proteinuria > 1 g/day or surveil-













mL) Gender Biopsy Indication Banff
2 68.11 1.08 2.1 0.92 10.7  Male Acute Graft Dysfunction Normal
3 45.38 1.64 1.73 0.475 8.1  Male Acute Graft Dysfunction Normal
4 28.19 2.85 1.9 0.6 9.8  Male Delayed Graft function ABMR
1 67.77 3.64 1.17 1 5.2  Male Suerveillance IFTA II
5 55.21 2.33 1.54 0.25 12.3  Male Suerveillance IFTA I
6 32.22 2.98 0.8 0.4 8.6  Male Suerveillance Borderline
7 71.28 3.08 1.82 0.38 11.8  Male Suerveillance IFTA I
8 44.56 3.15 1.12 0.2 10.2  Female Suerveillance Normal
9 61.46 3.18 1.1  7.6  Female Suerveillance IFTA I
10 72.07 3.25 1.4 0.126 9.6  Male Suerveillance IFTA I
11 36.73 3.54 1.46 0.048 11.6  Male Suerveillance Normal
12 62.48 3.57 1.12 0.2 7.1  Male Suerveillance IFTA I
13 69.92 3.7 1.42 0.318 11.6  Male Suerveillance IFTA I
14 44.73 3.84 1.34 0.13 7.5  Male Suerveillance Normal
15 70.34 3.87 1.62 0.327 9.3  Male Suerveillance IFTA II
16 39.07 4.13 1.15 0.204  158 Female Suerveillance IFTA I
17 39.07 4.36 0.8 0.53 11  Female Suerveillance ABMR
18 48.02 4.49 1.2 0.241 10.9  Male Suerveillance Normal
Mean 53.15 3.26 1.381 0.371 9.58 158.00    












mL) Gender Biopsy Indication Banff
1 64.9 3.8 2.5  10.8  Male Acute Graft Dysfunction ABMR
2 35.95 7.61 1.89 0.84 14  Male Acute Graft Dysfunction IFTA II
3 71.26 10.92 2.33 0.2 5.8  Male Acute Graft Dysfunction IFTA II 
4 79.94 2.82 2.4 0.45 6.9  Male Acute Graft Dysfunction IFTA II 
5 72.11 1.8 1.7 0.7  240 Male Acute Graft Dysfunction ATN 
6 45.52 0.95 0.95 4.07 10.6  Female Proteinuria FSGS Recurrence
7 75.91 2.85 1.7 0.17 10.9  Male Surveillance Borderline
8 66.94 4.59 1.1 0.097 14.2  Female Surveillance Borderline
9 74.7 3.77 1.2 0.1 7.1  Female Surveillance Borderline 
10 58.11 4.69 1.55 0.287 15.3  Male Surveillance IFTA II
Mean 64.53 4.38 1.731 0.771 10.62 240.00    
SEM 4.47 0.93 0.17 0.40 1.09 --    
ABMR: Antibody-mediated rejection, IFTA: interstitial fibrosis and tubular atrophy, ATN: acute tubular necrosis, Borderline: borderline rejection. FSGS: Focal segmental 
glomerulosclerosis. TP: Transplantation. 1Different from healthy volunteers group (Student’s t-test with Welch correctiont, P < 0.05).
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Table S2. Individual clinical data of Chronic Kidney Disease (CKD) patients group
CHRONIC KIDNEY DISEASE (CKD) PATIENTS
Patient Age (years) Creatinine (mg/dl) eGFR (MDRD-4) Proteinuria (g/day) Gender CKD Stage
1 63.7 2.12 31.82 0.338 Male III
2 61.28 1.41 51.39 1.836 Male III
3 36.39 1.91 44 0.102 Male III
4 56.28 1.47 48.84 0.034 Male III
5 41.31 2.77 25.56 3.031 Male IV
6 56.19 1.73 30.56 0.145 Female III
7 60.98 1.31 56.13 0.051 Male III
8 34.83 3.02 17.78 0.39 Male IV
9 65.19 1.91 26.45 0.483 Female IV
Mean 52.91 1.961 36.95 0.711
SEM 4.01 0.20 4.48 0.34
1Different from healthy volunteers group (Student’s t-test with Welch correction, P < 0.05).
Table S3. Individual clinical data of healthy volunteers group
HEALTHY VOLUNTEERS
Healthy volunteer Age (years) Creatinine (mg/dl) Proteinuria (g/day) Gender
1 34 0.98 Negligible Male
2 29 0.86 Negligible Female
3 29 0.9 Negligible Female
4 26 0.93 Negligible Male
5 34 0.9 Negligible Male
6 24 0.72 Negligible Female
7 32 0.63 Negligible Female
8 31 0.68 Negligible Female
9 32 0.68 Negligible Female
10 51 0.74 Negligible Male
11 40 0.55 Negligible Female
12 50 0.72 Negligible Male
13 59 0.61 Negligible Female
Mean 36.23 0.76 --
SEM 2.97 0.04 --
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Table S4. Clinical data of lung transplanted patients group 
LUNG TRANSPLANTED PATIENTS
Patient 1 Patient 2
Gender Age (years) Gender Age (years)
Male 45 Female 60
Months from TP Sample Creatinine (mg/dl) CsA (ng/ml)
Months 
from TP
Sample Creatinine (mg/dl) FK-506 (ng/ml)
Pre-TP • 0.8 0 Pre-TP • 0.89 0
1 • 0.96 206 2 • 0.7 15
3 • 1.15 415 3 • 0.71 8.1
4 • 1.1 276 4 • 0.71 14
6 1.6 16.5
Patient 3 Patient 4
Gender Age (years) Gender Age (years)
Male 33 Male 53
Months from TP Sample Creatinine (mg/dl) FK-506 (ng/ml)
Months 
from TP
Sample Creatinine (mg/dl) CsA (ng/ml)
Pre-TP • 0.69 0 Pre-TP • 0.93 0
0.25 • 1.54 16.4 0.25 1.64 222
1 • 1.98 5.3 0.5 • 1.1 227
1.5 • 0.82 6.6 1 0.96 574
2 • 0.87 8.4 2 • 0.86 421
3 0.83 272
6 0.96 339
9 • 0.88 162
10 • 1.89 355
Serial creatinine and FK-506 levels of 4 lung transplanted patient. (•) Urine sample was collected at that point of time.
Figure S1. Urinary levels of fascin-1 are not related to systemic blood levels of FK-506. Systemic blood levels of 
FK-506 were analyzed in kidney transplanted patients attending to isometric vacuolization of tubular cells (A) and 
urinary fascin-1 levels (B). There were no differences in blood FK-506 levels in kidney transplanted patients showing 
isometric vacuolization compared with those with normal tubular histology (A) and no relation was observed when 
correlating urinary fascin-1 levels with blood FK-506 levels (r2 = 0.12, P > 0.05) (B). Data were analyzed using a “t” 
test with Welch correction and correlation was performed with Pearson r coefficient.
